Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
My first interview with Zenopa went really well and I was made to feel at ease immediately. From the first day.
Rachel , 2014

Sandoz begins phase III trial of biosimilar etanercept

24 June 2013 17:30 in Consumer Healthcare News


Sandoz has announced the launch of a phase III trial of its new biosimilar etanercept, for the treatment of moderate to severe chronic plaque-type psoriasis.

This therapy is a biosimilar version of Enbrel, a tumour necrosis factor alpha inhibitor from Amgen that is approved for the treatment of rheumatoid arthritis, psoriasis and other conditions.

Sandoz's clinical programme was developed in consultation with regulatory authorities in the US and EU, with results from the study expected to support regulatory submissions in both territories.

Extensive preclinical and clinical data has demonstrated that the Sandoz biosimilar is highly similar to Enbrel, thereby justifying the progression to phase III testing.

Dr Mark McCamish, the company's head of global biopharmaceutical development, said: "Sandoz remains steadfast in its commitment to significantly increase worldwide access to essential, high-quality and life-enhancing biopharmaceuticals."

The firm's portfolio of around 1,100 medicines is currently available to more than 90 percent of the world's population.ADNFCR-8000103-ID-801603369-ADNFCR

Other news stories from 24/06/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd